Použité zdroje

BLACK, L. (2025) *3 healthy California residents die after ingesting synthetic kratom*. SFGATE, 13. 9. 2025.

Boyer, E.W., Babu, K.M., Adkins, J.E., McCurdy, C.R., Halpern, J.H. (2008). Self-treatment of opioid withdrawal using kratom (Mitragyna speciosa Korth.). Addiction 103, 1048–1050.

Burkill, I. H., & Haniff, M. (1930). *Malay village medicine: Prescription and practices*. Gardens' Bulletin, Straits Settlements, 6, 167–332.

Cinosi, E., Martinotti, G., Simonato, P., et al. (2015). Following „the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. *Biomed Research International*, 707-709.

Contorno, S. (2023, December 9). *Tampa Bay Times tested 20 kratom products. Here's what we found*. Tampa Bay Times.

Eliášek, A. (2023) Vzorce užívání kratomu u mladistvých a dospělých uživatelů kratomu na území České republiky. Bakalářská práce. Univerzita Palackého v Olomouci, Filozofická fakulta.

Eudaley, S. T., Brooks, S. P., & Hamilton, L. A. (2023). Case Report: Possible Serotonin Syndrome in a Patient Taking Kratom and Multiple Serotonergic Agents. *Journal of pharmacy practice, 36* (6), 1523–1527.

European Union Drugs Agency. (n.d.). *Kratom: Drug profile*. Publications Office of the European Union. Retrieved April 17, 2025, from https://www.euda.europa.eu/publications/drug-profiles/kratom_en

Grundmann, O. (2017). Patterns of kratom use and health impact in the US—Results from an online survey. *Drug and Alcohol Dependence,* 176, 63–70.

Gutridge, A. M., Robins, M. T., Cassell, R. J., Uprety, R., Mores, K. L., Ko, M. J., Pasternak, G. W., Majumdar, S., & van Rijn, R. M. (2020). G protein-biased kratom-alkaloids and synthetic carfentanil-amide

opioids as potential treatments for alcohol use disorder. *British journal of pharmacology,* 177 (7), 1497–1513.

Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H., Suhaimi, F. W., Vadivelu, R.... & Müller, C. P. (2013). From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. *Neuroscience & Biobehavioral Reviews, 37* (2), 138–151.

Havemann-Reinecke, U. (2011). Kratom and alcohol dependence: clinical symptoms, withdrawal treatment and pharmacological mechanisms – a case report. *European Psychiatry, 26* (Suppl. 1), 50.

Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2018). Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. *Addiction Biology,* 23 (4), 560–567.

Huisman, G., Menke, M., Grundmann, O., Schreiber, R., & Mason, N. (2023). Subjective differences in effects between kratom strains: An online survey. *International Journal of Environmental Research and Public Health,* 20(14), 6425.

Huisman, J., Su, M. R., Klumpers, L. E., & Ramaekers, J. G. (2023). Examining the psychoactive differences between kratom strains: A double-blind, placebo-controlled, randomized crossover trial. *Journal of Psychopharmacology,* 37(8), 790–801.

JAS – Abstinenti Jablonec (2024, 12. 5.) *ŠTĚPÁN - závislost na KRATOMU OD 15 LET, přes epileptické záchvaty k ABSTINENCI!!!* [Video]. YouTube. https://www.youtube.com/watch?v=zlLbyvNCrx8

Jirka vysvětluje věci (2025, září 8). *Temná stránka kratomu* [Video]. YouTube. https://www.youtube.com/watch?v=CNyVobQlno8.

Kong, W. M., Chik, Z., Ramachandra, M., Subramaniam, U., Aziddin, R. E. R., & Mohamed, Z. (2011). Evaluation of the Effects of *Mitragyna speciosa* Alkaloid Extract on Cytochrome P450 Enzymes Using a High Throughput Assay. *Molecules*, 16(9), 7344-7356.

Krotulski, A. J., Denn, M. T., Brower, J. O., Papsun, D. M., Logan, B. K. (2025) Evaluation of Commercially Available Smoke Shop Products Marketed as „7-Hydroxy Mitragynine“ & Related Alkaloids, *Center for Forensic Science Research and Education, United States.*

Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. *Neuropharmacology*, 134, 108–120.

Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V.…& Sames, D. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. *ACS Central Science,* 5 (6), 992–1001.

Matsumoto, K., Horie, S., Ishikawa, H., Takayama, H., Aimi, N., Ponglux, D., & Watanabe, K. (2004). Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb *Mitragyna speciosa*. *Life Sciences,* 74 (17), 2143–2155.

Matsumoto, K., Horie, S., Takayama, H., Ishikawa, H., Aimi, N., Ponglux, D., Murayama, T., & Watanabe, K. (2005). Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. *Life sciences,* 78(1), 2–7.

Powell, L., Ryser, T., Morey, G. & Cole, R. (2022). Kratom as a novel cause of photodistributed hyperpigmentation. *JAAD Case Reports,* 28 (7).

Prozialeck, W. (2016). Update on the Pharmacology and Legal Status of Kratom. *Journal of Osteopathic Medicine,* 116 (12), 802-809.

Prozialeck, W. C., Jivan, J. K., & Andurkar, S. V. (2012). Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. *The Journal of the American Osteopathic Association,* 112 (12), 792–799.

Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms, and craving in regular users. *Drug and Alcohol Dependence,* 139, 132–137.

Singh D., Narayanan S., Vicknasingam B, Corazza O, Santacroce R, Roman-Urrestarazu A. (2017). Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. *Human Psychopharmacology: Clinical and Experimental,* 31 (5), 356–365.

Suwanlert, S. (1975). A study of kratom eaters in Thailand. *Bulletin on Narcotics,* 27(3), 21–27.

Swogger, M. T., Hart, E., Erowid, F., Erowid, E., Trabold, N., Yee, K., Parkhurst, K. A., Priddy, B. M., & Walsh, Z. (2015). Experiences of Kratom Users: A Qualitative Analysis. *Journal of psychoactive drugs,* 47 (5), 360–367.

University of Florida. (n.d.). *Kratom.* University of Florida College of Pharmacy. Dostupné z https://pd.pharmacy.ufl.edu/research/kratom/ [cit. 2025-02-06].

U.S. Food and Drug Administration (2025, July 29). *FDA and kratom.* https://www.fda.gov/news-events/public-health-focus/fda-and--kratom

U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2025). *7-Hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat.* https://www.fda.gov/media/187899/download

Walton, S. E., Denn, M. T., Quinter, A. D., McDowell, A., DeBord, J. S., Logan, B. K., & Krotulski, A. J. (2025). *7-Hydroxy mitragynine – NPS Discovery new drug monograph.* Center for Forensic Science Research and Education (CFSRE), United States.

Wray, I. (1907). Biak: an opium substitute. *Journal of the Federated Malay States Museums* (2), 53.